Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01732913
Study type Interventional
Source Gilead Sciences
Contact
Status Terminated
Phase Phase 3
Start date January 16, 2013
Completion date May 18, 2016

See also
  Status Clinical Trial Phase
Terminated NCT01732926 - Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Phase 3